Fluperlapine
Fluperlapine is a drug that was developed by Janssen Pharmaceutica in the 1970s. It is classified as an atypical antipsychotic and antidepressant. However, it was never marketed.
Pharmacology[edit | edit source]
Fluperlapine is known to bind to the serotonin and dopamine receptors. It has high affinity for the 5-HT2A, 5-HT2C, D1, and D2 receptors. It also has moderate affinity for the 5-HT1A, 5-HT6, and 5-HT7 receptors.
Clinical Trials[edit | edit source]
Fluperlapine has been tested in clinical trials for the treatment of schizophrenia and depression. However, it was found to have a high incidence of side effects, including sedation and weight gain, which led to its discontinuation.
See Also[edit | edit source]
Fluperlapine Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD